• 2016March
      BPI start share-holding system reform.

    • 2015BPI has accumulated 10 new application for invention patents, including three new authorized invention patents.

    • 2015November
      BPI merged  one unique API production base in AnHui Province and built multiple production amplication.

    • 2014November
      BPI passed the review of Shanghai hi-tech enterprise confirmation.

    • 2014September
      BPI was authorized as ‘Shanghai patent pilot enterprises’.

    • 2014March
      Through further cooperation, BPI moved the production gravity from manufacturing site in Zhejiang to GMP manufacturing Site in Chongqing- Chongqing Southwest No.2 Pharmaceutical Factory Co., Ltd.

    • 2013August 
      BPI moved it’s marketing, accounting and executive departments from C7 to C3 in Xinfei Corporation Park. The former office C7 was reformed to be R&D and Quality center.
      BPI applied for a new authorization of Invention patent.

    • 2012February
      BPI won 2 authorization of Shanghai High-tech achievement transformation project. 
      BPI won 3 authorization of Invention patent and applied for another new one. 

    • 2012January 
      BPI thoroughly moved it’s headquarter into Xinfei Corporation Park, Songjiang District, Shanghai and reorganized marketing, R&D and Quality departments.

    • 2011July
      BPI obtained ISO9001 certification and strictly follows the quality requirements of cGMP and ISO9001.
      BPI won the prize of Shanghai hi-tech enterprise confirmation. BPI won 3 authorization of Invention patent. BPI applied the invention patent for Irinotecan Hydrochloride. BPI was authorized to be responsible for the project of ‘Innovation fund for middle and small sized enterprises’ in Shanghai.

    • 2010May
      Awarded the second prize of ‘2008~2009 Songjiang Science and Technology progress’. 
      BPI won 1 authorization of Invention patent and applied for two. 
      BPI was authorized to be responsible for the project of ‘Innovation fund for middle and small sized enterprises’ in Songjiang District.

    • 2010The total staff reached to 80 people. BPI involved strategic stakeholders and established Huangyan factory in Zhejiang.
      Huangyan factory officially went into operation in May and gained first batch of qualified product in June with qty 200KG.

    • 2009July 
      BPI and Shanghai University of Engineering Science jointly set up research lab to undertake "Commissioner of Shanghai Science and Technology" project.
      BPI applied for three more patents.

    • 2009Mar.
      BPI submit DMF documents to the FDA about the cooperation project (Irinotecan Hydrochloride, Docetaxel) and received the registration No.

    • 2009March
      BPI moved its executive office to Tamson Business Centre,Pudong, Shanghai.

    • 2009February
      The program of ‘7-ethyl-10-hydroxycampthothecin’ was assessed as High-tech achievement transformation project in Shanghai.

    • 2008BPI applied for a national patent for Purification Method of Camptothecin compounds.

    • 2007December
      The patent about morpholine derivatives have been offered the national patent application number and PCT application number.

    • 2007The total staff reached to 30 people. Founders withdrew from BPI, and insteadly management started to hold shares, regulated company system and established integrated functional departments.

    • 2006July
      BPI applied for its first inventive patent.

    • 2006The total staff reached to 20 people, mainly R&D and analysts.

    • 2005November 
      BPI moved its office to Shanghai CaoHeJing Hi-tech Park and built about 1 square kilometers labs.

    • 2005The total staff reached to 10 people and owned its independent analysts.

    • 2004Three employees in initial team started running company, including Qian Li and Ping Zhang who are still work for Biocompounds.

    • 2003October
      BPI set up its headquarter in Zhangjiang Innopark,Pudong,Shanghai.

    • 2003March
      Three founders established Biocompounds Pharmaceutical Incorporation (BPI).